The year of the small buyout
Biopharma takeouts in the $1-5bn range jumped in 2021, as rising valuations made their mark.
In a quiet year for takeouts, who was buying?
Small and mid-sized developers upped deal-making activity last year, a deep dive into M&A data finds.
J&J breathes some more life into plamotamab and CD28
Two Xencor approaches with questions around them receive the backing of Johnson & Johnson.
Biopharma takeovers dry up
If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?
Why not bapineuzumab?
Like Aduhelm this long-discontinued amyloid beta MAb reduced brain beta amyloid; so have several other industry projects.
Fortunes diverge for solo drug launchers
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
Recycling pays off for Mereo
The company has spent five years buying in discontinued projects, and at last has managed to sell one of these on at a nice profit.
Mapping the transatlantic divide for biotech flotations
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
